October 2025 in “International Journal of Molecular Sciences” This study identified changes in immune activation, ferroptosis, and structural genes in alopecia areata subtypes, suggesting molecular markers that might help understand disease variability and guide future treatments.
September 2025 in “Figshare” This study conducted a scoping review and meta-analysis revealing a complex chemokine profile in alopecia areata patients, with elevated Th1, Th2, and other immune pathway chemokines, suggesting broader immunomodulatory strategies may help address the disease's multifaceted immune dysregulation.
September 2025 in “Figshare” In this scoping review and meta-analysis, researchers found that patients with alopecia areata exhibit complex chemokine profiles, with elevated levels of Th1, Th2, and other immune pathway-associated chemokines, suggesting the potential for broad immunomodulatory strategies to address the disease's immune dysregulation.
August 2025 in “International Journal of Molecular Sciences” This meta-analysis found that among topical OTC treatments for male androgenetic alopecia, minoxidil 5% applied twice daily was the most effective in increasing total hair density over 24 weeks.
August 2025 in “Frontiers in Immunology” This meta-analysis found that patients with alopecia areata, particularly those with more extensive forms like alopecia totalis and universalis, may face a higher risk of cardiovascular disease, though no links were found with specific conditions like ischemic stroke or myocardial infarction.
August 2025 in “Figshare” This meta-analysis found that patients with alopecia areata, especially those with alopecia totalis or alopecia universalis, have an increased risk of cardiovascular disease, possibly due to shared immunological mechanisms and systemic inflammation. Further research is needed to confirm these findings and explore underlying mechanisms.
August 2025 in “Figshare” This meta-analysis found that patients with alopecia areata, especially those with more severe forms like alopecia totalis or universalis, may have an increased risk of cardiovascular disease, suggesting a potential link between the systemic inflammation in AA and cardiovascular risk.
July 2025 in “Derecho y cambio social.” This cross-meta-analysis examined policosanol biorefining methods in 18 Ibero-American countries, reporting that Cuba, Spain, Brazil, Chile, Mexico, and Portugal show significant advances, but highlighted the need for better coordination between academia and industry for improved yield efficiency.
February 2025 in “International Journal of Molecular Sciences” This meta-analysis of animal studies found that alkaloids have potential anti-influenza and anti-inflammatory effects, correlating with improved viral titers and survival rates, though they did not effectively reduce TNF-α and IL-6 levels. Extensive further studies are needed to confirm these findings before considering clinical application.
January 2025 in “Dermatologic Surgery” This meta-analysis and systematic review found that botulinum toxin injections significantly increased hair count in patients with androgenetic alopecia compared to controls, indicating promising efficacy and good safety.
January 2025 in “Figshare” This meta-analysis concluded that compound glycyrrhizin combined with conventional treatments enhanced hair regrowth in alopecia areata patients, though it was associated with some mild adverse effects like oedema.
January 2025 in “Figshare” This meta-analysis concluded that compound glycyrrhizin combined with conventional treatments improved hair regrowth in patients with alopecia areata, though it was associated with mild adverse events like edema.
November 2024 in “International Journal of Scientific Reports” This meta-analysis found that while both Dienogest and GnRH analogues effectively managed endometriosis-related pain, Dienogest reduced recurrence rates and hot flushes but increased irregular bleeding, making it a safer option due to fewer side effects.
October 2024 in “International Journal of Dermatology” In this meta-analysis, researchers found that oral and topical minoxidil treatments for androgenetic alopecia had similar efficacy in improving hair density and diameter, but oral minoxidil resulted in a higher incidence of hypertrichosis compared to topical use.
September 2024 in “Journal of the American Academy of Dermatology” This meta-analysis found that smoking is significantly associated with increased odds of developing and progressing androgenetic alopecia, with higher risks observed in men smoking at least 10 cigarettes daily.
September 2024 in “Journal of the American Academy of Dermatology” Dermocosmetics significantly reduce itch and skin sensitivity in atopic dermatitis patients.
This meta-analysis reports that ritlecitinib significantly improved hair growth in alopecia areata patients compared to placebo, although its potential requires further clinical exploration.
July 2024 in “Journal of Investigative Dermatology” JAK inhibitors improve hair growth in alopecia areata, especially in patchy types.
This study reported that Sintilimab combined with chemotherapy may improve outcomes in advanced NSCLC patients but carries a higher risk of certain side effects, including hypothyroidism.
This research review found that spironolactone can significantly improve acne severity more effectively than a placebo, with 73.3% of patients reporting satisfaction despite a 26.7% rate of adverse events among the 1,548 participants studied.
March 2024 in “Cancer Research” This meta-analysis found that men with vertex balding at age 40 or older may have a modestly increased risk of prostate cancer, with a pooled relative risk of 1.08, but no significant association was observed with frontal balding.
This research aims to evaluate 6-month changes in total and terminal hair density, with data quality assessed using Cochrane risk of bias tools, but does not report specific study results yet.
January 2024 in “Journal of Cosmetic Dermatology” This study found that men who smoke are more likely to develop androgenetic alopecia and experience disease progression compared to non-smokers.
January 2024 in “Gynecologic and Obstetric Investigation” This meta-analysis reported no significant differences in vocal alterations and quality of life between women with PCOS and control groups, yet emphasized that the findings are limited by a lack of high-quality studies, suggesting further research is needed.
January 2024 in “International Wound Journal” Combination antibiotic therapy is more effective but causes more side effects.
December 2023 in “Migration letters” This meta-analysis reviewed 25 studies and suggested that herbal interventions could improve reproductive health in women with PCOS, showing benefits across measures such as Body Mass Index, hirsutism, and insulin levels, although results were mixed for fasting glucose and FSH levels.
November 2023 in “Journal of Investigative Dermatology” This research investigated immune cell involvement in various types of inflammatory alopecia by analyzing gene expression data from scalp samples, revealing distinct cellular changes in conditions like Alopecia Areata, Frontal Fibrosing Alopecia, Lichen Planopilaris, and Central Centrifugal Cicatricial Alopecia, which may inform future therapeutic targets.
November 2023 in “Journal of Investigative Dermatology” JAK inhibitors are effective and generally safe for treating alopecia areata, but monitoring for side effects is important.
September 2023 in “Journal of the American Academy of Dermatology” This meta-analysis found a significant positive association between frontal fibrosing alopecia and both sunscreen and moisturizer use, with the moisturizer association significant only in males.
August 2023 in “Aesthetic Plastic Surgery” This meta-analysis found that PRP monotherapy improved hair density in androgenetic alopecia patients but did not affect hair diameter, with stronger effects observed in male subjects.